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Abstract
Background: Cyclin-dependent kinase 5 (CDK5) is an atypical CDK which plays a vital role in several cancers via
regulating migration and motility of cancer cells. However, the clinicopathological impact and function of CDK5 in
lung cancer remain poorly understood. The present study was aimed at exploring expression and clinicopathological
significance of CDK5 in lung cancer.
Methods: There were 395 samples of lung tissue including 365 lung tumors (339 non-small cell lung cancers and 26
small cell lung cancers) and 30 samples of normal lung. CDK5 expression was detected by immunohistochemistry on
lung tissue microarrays.
Results: Over expression was detected in lung cancer compared with normal lung tissues (P = 0.001). Furthermore,
area under curve (AUC) of receiver operating characteristic (ROC) of CDK5 was 0.685 (95 % CI 0.564~0.751, P = 0.004). In
lung cancer, we also discovered close correlations between CDK5 and pathological grading (r = 0.310, P < 0.001), TNM
stage (r = 0.155, P = 0.003), and lymph node metastasis (r = 0.279, P < 0.001) by using Spearman analysis. In two
subgroups of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the expression of CDK5
was also higher than that of normal lung tissue, respectively (P = 0.001 and P = 0.004). Moreover, in NSCLCs,
Spearman analysis revealed that expression of CDK5 was correlated with TNM stages (r = 0.129, P = 0.017),
lymph node metastasis (r = 0.365, P < 0.001), and pathological grading (r = 0.307, P < 0.001), respectively. The
significant correlation was also found between CDK5 expression and TNM stages (r = 0.415, P = 0.049) and
lymphatic metastasis (r = 0.469, P = 0.024) in SCLCs.
Conclusions: The results of this present study suggest that the CDK5 expression is associated with several
clinicopathological factors linked with poorer prognosis.
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Background
Lung cancer is the most common type of cancer and
the leading cause of cancer-related deaths in the
world [1, 2]. In China, the incidence and the mortal-
ity of lung cancer increase rapidly, and now, lung
cancer is the first dominating cancer [3]. Non-small
cell lung cancer (NSCLC) is the most frequent (ap-
proximately 85 %) class of lung cancers [4, 5]. As a
result of the insufficiency of efficacious biomarkers
for early diagnosis, the majority of lung cancer pa-
tients are diagnosed in an advanced stage [6]. Al-
though there are increasing proofs of therapeutic
targets like EGFR, HER2, ALK, ROS1, BRAF, MET,
VEGF, and FGFR1 and perpetual endeavor in clinic,
the prognosis for patients with NSCLC still remains
poor, with only a 5-year survival rate of 15 % with
the normal therapy [7–9]. Therefore, there is an ur-
gent requirement to discover new stable and inde-
pendent biomarkers for prognosis and molecular
therapy for lung cancer.
Cyclin-dependent kinases (CDKs) are serine/threo-
nine kinases activated by cyclins [10]. CDK5 is a mem-
ber of CDKs and the investigation of CDK5 in cancer
is increasing. In addition to western blot analysis, im-
munohistochemistry has also been performed to de-
tect expression of CDK5 in cancer tissue [11]. CDK5
has been reported to be upregulated in prostate
cancer, breast cancer, medullary thyroid carcinoma,
pituitary adenoma, and hepatocellular carcinoma, and
CDK5 gene amplification was found in lung cancer
[11–16]. However, decreased expression of CDK5 was
detected in gastric cancer [17]. The results of the stud-
ies showed that CDK5 was greatly related to prolifera-
tion, migration, and motility of cancer cells [13–17].
Moreover, downregulation of CDK5 indicated higher
overall survival in multiple myeloma [18]. With regard
to prognostic implications, decreased expression of
CDK5 was associated with advanced clinical stage and
poor survival in gastric cancer patients and increased
CDK5 expression was correlated to high pathological
grading in breast cancer [11, 17]. So far, several arti-
cles have studied the potential role of CDK5 in lung
cancer in vitro [19–22]. However, only one paper
mentioned the clinical contribution of CDK5 in lung
cancer with only 95 NSCLC patients and without
small cell lung cancer (SCLC) cases by Liu et al. [23].
In the current study, we set up a larger sample size of
365 lung cancers, 3.8 times bigger than the previous
study performed by Liu et al. [23]. Hence, the object-
ive of this study was to explore the expression and
clinicopathological significance of CDK5 in lung can-
cers and investigate its potential role of CDK5 as a




This study was conducted with 395 samples including
365 lung cancers and 30 normal lung tissues. The fix-
ation was performed shorter than 15 min after surgical
removal of the tissue with neutral-buffered formalin
(10 %), and fixation time was 24–48 h according to the
tissue size. Two pathologists (Kanglai Wei and Gang
Chen) screened all the collected hematoxylin- and eosin-
stained sections and selected areas of the paraffin-
embedded tissue specimens that contained representa-
tive tumor or non-tumorous cells. Two tissue cores of
0.6 mm in diameter were taken from each donor block
sample and arrayed into a new blank recipient paraffin
block (35 mm × 22 mm × 5 mm) with a commercially
available microarray instrument (Beecher Instruments,
USA). Two TMA blocks included 150 cases (300 tissue
cores) and the third one comprised of 95 cases (190
tissue cores), respectively. The total lung material was
mounted into three blocks. The age range of lung can-
cer patients was from 19 to 84 years and was from 19
to 73 years of normal lung tissue. The mean age was
57.67 and 54.03 years for cancer and normal controls,
respectively. When lung cancer was separated into two
subgroups, there were 339 samples of NSCLCs and 26
samples of SCLCs. Furthermore, NSCLCs were composed
of 127 samples of adenocarcinomas, which included four
subtypes of 83 cases of acinar adenocarcinoma, 19 cases of
papillary adenocarcinomas,18 cases of bronchioloalveolar
cell carcinomas, and 7 cases of mucinous carcinomas.
NSCLCs also included 175 squamous cell carcinomas,
28 adenosquamous carcinomas, 8 undifferentiated
carcinomas, and 1 large cell carcinoma (Table 1).
Various clinicopathological factors of patients were
collected, including gender, age, pathological grading,
TNM stage, lymph node metastasis, tumor size, and
distal metastasis. The samples were obtained by random
selection of the lung cancer patients by surgery without
cancer-related treatment in the First Affiliated Hospital of
Guangxi Medical University from January 2010 to Decem-
ber 2012. Approval of this study was achieved from the
Ethical Committee of the First Affiliated Hospital of
Guangxi Medical University, clinical doctors and patients.
Moreover, two pathologists were responsible for the
diagnosis, independently.
Immunohistochemistry
Santa Cruz Biotechnology (Heidelberg, Germany) pro-
vided the CDK5 antibody (C-8,sc-173,1:50 dilution) for
immunostaining, and a ZSGB Kit (PV-6000, ZSGB,
Beijing, China) was used for the secondary antibody at
room temperature. CDK5 immunostaining score was de-
termined by both positive rate of stained tumor cells and
staining intensity. Concretely, the positive rate of stained
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tumor cells and the corresponding score were assigned
as follows: 0 (0 %), 1 (1–25 %), 2 (26–50 %), 3 (51–
75 %), and 4 (76–100 %). The intensity of CDK5 staining
was scored from 0 to 3, and the detailed standard was as
follows: 0 (no staining), 1 (weak staining), 2 (moderate
staining), and 3 (strong staining). Samples were scored
by the summation of the percentage of CDK5-positive
cells and staining intensity. The total score of immuno-
staining was more than two which was considered as
positive expression of CDK5. Immunostaining was
assessed and graded independently by two pathologists
(Kanglai Wei and Gang Chen).
Statistical analysis
The statistical analysis was conducted by SPSS 20.0
completely, and P values less than 0.05 were considered
statistically significant. The chi-square test was used in
the analysis of contrast of two groups, and when it
exceeded two groups, Kruskal-Wallis H test was per-
formed. Further, Spearman analysis was performed to
study the relationship between CDK5 expression and
clinicopathological characteristics. Moreover, we con-
ducted ROC curve to evaluate the diagnostic significance
of CDK5 in lung cancer, and the area under curve
(AUC) of CDK5 more than 0.5 was considered
significant.
Results
(CDK5) expression in lung cancer
CDK5-positive signaling located in the cytoplasm of the
tumor cells. Significantly increased expression of CDK5 in
lung cancer tissues (51.5 %, 188/365) was found as com-
pared to that in normal lung tissues (20 %, 6/30, P = 0.001,
Table 2, Fig. 1). Furthermore, we conducted ROC curve to
evaluate the diagnostic significance of CDK5 in lung cancer.
The AUC of CDK5 was 0.685 (95 % CI 0.564~0.751,
P = 0.004). However, there was no statistical significance be-
tween expression of CDK5 in NSCLC and SCLC. Concern-
ing the correlation between CDK5 expression and clinical
features, CDK5 was found to be related to several clinico-
pathological parameters (Table 3). The positive rate of
CDK5 expression was higher (68.3 %, 43/63) in advanced
stages (III and IV) than in early stages (I and II) (47.8 %,
143/299, P = 0.003, Table 3). Higher expression of CDK5
was found in lung cancer patients with lymphatic metasta-
sis (76.6 %, 98/128) compared to those without lymphatic
metastasis (37.6 %, 88/234, P < 0.001, Table 3). In
Table 2 CDK5 expression in lung cancer compared with normal lung tissue
Cancer and normal lung tissue n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Normal lung tissue 30 24(80.0) 6(20.0)
Cancer tissue 365 177(48.5) 188(51.5) −3.314 0.001
SCLC 26 11(42.3) 15(57.7) −2.880 0.004
NSCLC 339 166(49.0) 173(51.0) −3.225 0.001
Squamous cell carcinoma 175 88(50.3) 87(49.7) −3.013 0.003
Adenosquamous carcinoma 28 10(35.7) 18(64.3) −3.392 0.001
Undifferentiated carcinoma 8 3(37.5) 5(62.5) −2.324 0.020
Large cell carcinoma 1 1(100) 0(0) −0.490 0.624
Adenocarcinoma 127 64(50.4) 63(49.6) −2.929 0.003
Acinar adenocarcinoma 83 36(43.4) 47(56.6) −3.430 0.001
Papillary adenocarcinoma 19 12(63.2) 7(36.8) −1.288 0.198
Bronchioloalveolar cell carcinoma 18 10(55.6) 8(44.4) −1.785 0.074
Mucinous carcinoma 7 6(85.7) 1(14.3) −0.343 0.732
Non-small cell lung cancer (NSCLC) vs small cell lung cancer (SCLC) P = 0.513
Table 1 The classification of lung cancer
















This table was to classify the subtypes of lung cancer. Lung cancer is consisted
of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC
was composed of squamous cell carcinomas, adenosquamous carcinomas,
large cell carcinoma, undifferentiated carcinomas, and adenocarcinoma.
Furthermore, adenocarcinoma was composed of acinar adenocarcinoma,
papillary adenocarcinomas, bronchioloalveolar cell carcinomas, and
mucinous carcinomas
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pathological grading III (66.4 %, 87/131), CDK5 expression
was higher than that in pathological grading I (25.6 %,
10/39, P < 0.001) and there was an increasing trend for
CDK5 positive rate as the pathological grading in-
creased (P < 0.001, Table 3). In addition, Spearman co-
efficient of correlation was performed to investigate
the relationship between the expression of CDK5 and
clinicopathological parameters. It was showed that
there were close correlations between CDK5 expres-
sion and TNM stage (r = 0.155, P = 0.003), lymph node
metastasis (r = 0.279, P < 0.001), and pathological grad-
ing (r = 0.310, P < 0.001). A marginal correlation be-
tween CDK5 expression and distal metastasis has been
found (r = 0.102, P = 0.053). Besides, no significant
correlation between CDK5 expression and other clini-
copathological factors was discovered, such as gender,
age, and tumor diameter.
Cyclin-dependent kinases (CDK5) expression in non-small
cell lung cancer (NSCLC)
When lung cancer patients were separated into two sub-
groups of NSCLC and SCLC, we discovered that there
was higher positive rate in NSCLC compared with normal
lung tissues (P = 0.001, Table 4). Higher CDK5-positive
expression was also found in the subgroups of NSCLCs
including adenocarcinoma (P = 0.003), squamous cell car-
cinoma (P = 0.003), adenosquamous carcinoma (P = 0.001),
and undifferentiated carcinoma (P = 0.02), than that in the
normal lung tissue. After adenocarcinoma was further split
into four different types, remarkably higher expression of
CDK5 was found in acinar adenocarcinoma as compared
to normal lung tissues (P = 0.001, Table 4). When the rela-
tionship between CDK 5 expression and other parameters
was concerned in the patients with NSCLCs, higher CDK5
expression positive rate appeared in the advanced stages
(III and IV) (66 %, 35/53) compared with the early stages (I
and II) (48.3 %, 138/286, P = 0.018, Table 4) and the similar
result was found in lymph node metastasis (76.5 %, 88/115)
as compared to non-lymph node metastasis (37.9 %, 85/
224, P < 0.001, Table 4). In pathological grading III, the
positive expression of CDK5 was 66.2 % (86/130) in the
cases of NSCLC higher than that in pathological grading I
(25.6 %, 10/39)and II (42.4 %, 39/92, both P < 0.001, Table 4).
Borderline difference of CDK5 expression has been found
between distal metastasis (75 %, 12/16) and non-distal me-
tastasis (49.8 %, 161/323, P = 0.05, Table 4). Moreover,
Spearman analysis showed that the positive CDK5 expres-
sion in NSCLC was correlated with TNM stages (r= 0.129,
P = 0.017), lymph node metastasis (r = 0.365, P < 0.001),
and pathological grading (r = 0.307, P < 0.001). A marginal
correlation between CDK5 expression and distal metastasis
was also noticed (r = 0.107, P = 0.05).
Cyclin-dependent kinases (CDK5) expression in small cell
lung cancer (SCLC)
There were 26 patients of SCLC, and the positive rate
of CDK5 expression was 57.7 % (15/26), significant higher
compared to normal lung tissues (20 %, 6/30, P = 0.004). In
the patients with SCLC, higher expression of CDK5 was
found in female (100 %, 5/5) and lymph node metastasis
(76.9 %, 10/13) compared with that in male (47.6 %, 10/21,
P = 0.037) and without lymph node metastasis (30 %, 3/10,
P = 0.028, Table 5), respectively. Spearman coefficient of
correlation showed that the positive CDK5 expression in
SCLC was correlated with gender (r = 0.418, P = 0.034),
TNM stages (r = 0.415, P = 0.049), and lymph node metas-
tasis (r = 0.469, P = 0.024, Table 5).
Fig. 1 Immunohistochemical staining of CDK5 in lung tissue. Negative
expression of CDK5 was found in normal lung cancer tissue (a ×100,
b ×400) and significantly positive expression of CDK5 was detected in
the cytoplasm of squamous carcinoma (c ×100, d ×400), papillary
adenocarcinoma (e ×100, f ×400), bronchioloalveolar cell carcinoma
(g ×100, h ×400), small cell lung cancer (SCLC, i ×100, j ×400)
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Discussion
Cyclin-dependent kinase 5 (CDK5) is vital in neural cell
migration and differentiation and is activated by p35 or
p39 [24], and CDK5 is considered to be essential in
neuronal cells [25, 26]. Nevertheless, as a unique mem-
ber of cyclin-dependent kinases, the function of CDK5
beyond the nervous system has been demonstrated.
CDK5 also regulates cell proliferation by alterant expres-
sion and its downstream signaling pathways, especially
in cancer cells. Up to date, there has been a growing
number of evidence that CDK5 has an important effect
on cancer progression [27]. The expression of CDK5
was aberrant in several cancers, and CDK5 regulated the
proliferation of cancer cell in prostate cancer, medullary
thyroid carcinoma, and gastric cancer [14, 15, 17]. In
breast cancer, CDK5 was essential for the motility of
cancer cell [11]. Moreover, CDK5 can be used to predict
the prognosis of multiple myeloma [18]. In a word, the
role of CDK5 in cancer is attracting increasing attention.
To date, the expression of CDK5 was investigated in sev-
eral cancers [13, 15, 17]. Higher expression of CDK5
was observed in hepatocellular carcinoma, ampullary
adenocarcinoma, breast cancer, and medullary thyroid
carcinoma, and Zachary et al. confirmed the expression
of CDK5 was upregulated in colorectal, head/neck,
breast, lung, ovarian, lymphoma, prostatic, sarcoma,
myeloma, and bladder cancers via the Oncomine micro-
array online data mining software [11, 12, 18, 28]. How-
ever, downregulated expression of CDK5 was observed
in gastric cancer. Thus, CDK5 might be heterogeneously
expressed in different cancers.
In the present study, immunohistochemistry on lung
tissue microarrays was performed to explore the expres-
sion of CDK5 in lung cancer and normal lung tissues.
There was prominently higher expression of CDK5 in
lung cancer, independent of various pathological sub-
types, than in normal lung tissue. In the study of Liu et
al., CDK5 was upregulated in cancer tissue as compared
to benign pulmonary disease with a sample size of 95
non-small cell lung cancers (NSCLCs) [23]. Our study,
with a bigger sample size, approximately four times,
confirmed that increased expression of CDK5 could be
detected in lung cancer tissue compared with normal
lung tissue and further supported that CDK5 was con-
sidered as an oncogene in lung cancer. No significant
difference of CDK5 expression was found between
NSCLC and SCLC in this current study. Although
NSCLC and SCLC are commonly regarded as different
Table 3 CDK5 expression associated with the various clinicopathological parameters in lung cancer
Lung cancer n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Gender −0.884 0.377
Male 275 137(49.8) 138(50.2)
Female 90 40(44.4) 50(55.6)
Age(years) −0.418 0.676
<60 196 96(49.0) 100(51.0)
≥60 169 81(47.9) 88(52.1)
Pathological grading 25.060a <0.001
I 39 29(74.4) 10(25.6)
II 92 53(57.6) 39(42.4)
III 131 44(33.6) 87(66.4)
TNM −2.944 0.003
I–II 299 156(52.2) 143(47.8)
III–IV 63 20(31.7) 43(68.3)
LNM −7.080 <0.001
Yes 128 30(23.4) 98(76.6)
No 234 146 (62.4) 88(37.6)
Tumor diameter (cm) −1.653 0.098
≤7 314 158(50.3) 156(49.7)
>7 48 18(37.5) 30(62.5)
Distal metastasis −1.931 0.054
Absent 346 172(49.7) 174(50.3)
Present 16 4(25.0) 12(75.0)
aKruskal-Wallis H test was performed between the groups of pathological grading
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diseases owing to their distinct biology and genomic ab-
normalities, the role and function of CDK5 may be con-
sistent, as CDK5 level was both upregulated in NSCLC
and SCLC tissues than the non-cancerous lung. How-
ever, the exact role of CDK5 in SCLC needs further in-
vestigation, since only a limited sample size (n = 26) was
included in the current study. Taken together, CDK5
might be a potential biomarker of lung cancer despite its
histology types.
The regulative mechanism of CDK5 in several cancers
was investigated. CDK5 regulates DNA damage response
via phosphorylating Ataxia telangiectasia mutated
(ATM) kinase and thereby affecting its downstream sig-
nal pathways which was crucial to progression of hepa-
tocellular carcinoma [12]. In ampullary adenocarcinoma,
over expression of nestin/CDK5 was involved in several
oncogenic pathways (the activation of NOTCH, TGF-β1,
or PDGFR pathways) that facilitated invasiveness of
Table 4 The correlation of CDK5 with diverse clinical clinicopathological factors in NSCLC
NSCLC n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Gender −0.406 0.685
Male 254 126(49.6) 128(50.4)
Female 85 40(47.1) 45(52.9)
Age(years) −0.080 0.936
<60 181 89(49.2) 92(50.8)
≥60 158 77(48.7) 81(51.3)
Pathological grading 24.58a <0.001
I 39 29(74.4) 10(25.6)
II 92 53(57.6) 39(42.4)
III 130 44(33.8) 86(66.2)
TNM −2.376 0.018
I–II 286 148(51.7) 138(48.3)
III–IV 53 18(34.0) 35(66.0)
LNM −6.717 <0.001
Yes 115 27(23.5)) 88(76.5)
No 224 139(62.1) 85(37.9)
Tumor diameter (cm) −1.145 0.252
≤7 295 148(50.2) 147(49.8)
>7 44 18(40.9) 26(59.1)
Distal metastasis −1.962 0.05
Absent 323 162(50.2) 161(49.8)
Present 16 4(25.0) 12(75.0)
Histology 3.646a 0.456
Adenocarcinoma 127 64(50.4) 63(49.6)
Squamous cell carcinoma 175 88(50.3) 87(49.7)
Adenosquamous carcinoma 28 10(35.7) 18(64.3)
Undifferentiated carcinoma 8 3(37.5) 5(62.5)
Large cell carcinoma 1 1(100) 0(0)
Adenocarcinoma classification 6.508a 0.089
Acinar adenocarcinoma 83 36(43.4) 47(56.6)
Papillary adenocarcinoma 19 12(63.2) 7(36.8)
Broncholoalveolar cell carcinoma 18 10(55.6) 8(44.4)
Mucinous carcinoma 7 6(85.7) 1(14.3)
Pathological grading I vs. II Z = −1.805, P = 0.071, I vs. III Z = −4.466, P < 0.001, II vs. III Z = −3.508, P < 0.001. Acinar adenocarcinoma vs. mucinous Z = −2.144,
P = 0.032. There were no differences of expression of CDK5 in other subgroups
aKruskal-Wallis H test was performed when the data were divided into more than two groups
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cancer [28]. In breast cancer, CDK5 takes part in
epithelial-mesenchymal transition induced by TGF-
β1which is vital for tumor metastasis [11]. In medullary
thyroid carcinoma, CDK5 is essential to tumorigenesis
and progression by retinoblastoma protein (Rb) and in-
hibition of Rb reduced proliferation of medullary thyroid
carcinoma [15]. The mechanisms of tumorigenesis and
progression in lung cancer might be similar to the
mechanisms aforementioned in other cancers in consid-
eration of a consistent trend of CDK5 expression. How-
ever, this hypothesis needs to be verified with in vitro
and in vivo studies.
Though expression of CDK5 was detected in lung can-
cer tissue and regulative mechanism of CDK5 was inves-
tigated in other cancers, the mechanism and exact role
of CDK5 in the carcinogenesis and development of lung
cancer remain unclear. A study of Korean population
shows that CDK5 promoter polymorphisms contribute
to the genetic susceptibility to lung cancer [20]. As one
of the downstream components of the EGFR-family-
signaling pathway, the gene of CDK5 was amplified in
lung cancer and it might be the common mechanism of
oncogene activation in carcinogenesis [16]. Tripathi et
al. demonstrated that the CDK5 phosphorylates four ser-
ines located N-terminal to the Rho-GTPase activating
protein(Rho-GAP) domain in DLC1(deleted in lung can-
cer 1), a tumor suppressor protein, and thereby activates
DLC1 [22]. Through the reconstruction of an integrated
genome-scale co-expression network, Bidkhori et al. ex-
hibited that CDK5 played a vital role in cell cycle pro-
gression in lung adenocarcinoma [19]. The studies above
of CDK5 in lung cancer suggested CDK5 may play an
oncogenic role in lung cancer.
In addition to the expression of CDK5 in cancer tis-
sues, the relationship between CDK5 and pathological
parameters has been paid more and more attention to.
There were a few researches of the relationship be-
tween CDK5 and clinical factors in the patients with
cancers. In breast cancer, upregulated expression of
CDK5 was related to higher grading (grading III) [11].
In multiple myeloma, downregulated expression of
cdk5 predicted favorable overall survival after bortezo-
mib treatment [18]. Liu et al. demonstrated that
higher expression of CDK5 was correlated with low/
undifferentiated, high pathological stage, lymph node
metastasis, shorter median survival, and lower 5-year
overall survival in the patients with NSCLC [23]. Simi-
larly, with a larger sample size, the consistent trend in
this current study was confirmed that higher positive
rate of CDK5 expression was greatly correlated with
unfavorable clinicopathological parameters, including
advanced TNM stage, lymphatic metastasis, and high
pathological grading, which commonly indicate poorer
prognosis. Thus, CDK5 might be used for the predic-
tion to prognosis of lung cancer.
Further, Demelash et al. [21] demonstrated that
CDK5 played a vital role in the regulation of lung
cancer cell migration and invasion through Wound
closure and Boyden chamber assay and certified that
achaete-scute homologue-1 (ASH1), a basic tran-
scription factor which was expressed in lung cancer
cells with neuroendocrine features [29], could stimu-
late migration of lung cancer cells through CDK5/
p35 pathway. The mechanism may support that
CDK5 was closed related to lymphatic metastasis in
lung cancer.
Table 5 The correlation of CDK5 expression with various clinical pathological factors in SCLC
SCLC n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Gender −2.089 0.037
Male 21 11(52.4) 10(47.6 )
Female 5 0(0) 5(100)
Age(years) −0.515 0.606
<60 15 7(46.7) 8(53.3)
≥60 11 4(36.4) 7(63.6)
TNM −1.948 0.051
I–II 13 8(61.5) 5(38.5)
III–IV 10 2(20.0) 8(80.0)
LNM −2.201 0.028
Yes 13 3(23.1) 10(76.9)
No 10 7(70.0) 3(30.0)
Tumor diameter (cm) −1.888 0.059
≤7 19 10(52.6) 9(47.4)
>7 0(0) 4(100)
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Conclusions
In summary, in this current study, the expression of
CDK5 was investigated by lung tissue microarrays and
immunohistochemistry. We demonstrated that CDK5
was highly expressed in lung cancer, including non-small
cell lung cancer and small cell lung cancer, compared to
normal lung tissue. Higher positive rate of CDK5 was
associated with several clinicopathological parameters,
which are representative of the progression and deterior-
ation of lung cancer. These results suggest that the
CDK5 expression associated with several unfavorable
clinicopathological factors linked with poorer prognosis.
Nevertheless, further plans are needed to explore the po-
tential function of CDK5 in vitro and in vivo in the car-
cinogenesis of and progression in lung cancer.
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